SOURCE: BioMedReports


May 19, 2010 11:24 ET

Vatican Endorsement Seals NBS's Status as the Major Play in Regenerative Medicine

LOS ANGELES, CA--(Marketwire - May 19, 2010) -  BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors, is reporting that several key announcements by Neostem (NYSE Amex: NBS) could send shares of the company soaring.

NBS announced this morning that the Vatican's Pontifical Council for Culture today announced a joint 5 year initiative between the companies and their charitable organizations to expand research and raise awareness of adult stem cell therapies. As BioMedReports understands it, the Vatican has endorsed NBS's method of extraction and storage of autologus (self-derived) adult stem cells as well as the growing number of NBS's proprietary treatments for these cells in the orthopedic, cardiovascular, cosmetic areas.

The Vatican is especially interested in NBS's VSEL technology which we identified in our Friday alert. VSEL, very small embryonic like, adult stem cells, have all the characteristics of embryonic stem cells but avoid the rejection issues that occur with using another person's embryonic stem cells. The weight of the Vatican's political, financial and promotional backing of such technologies makes NBS the leading stem cell play.

The Vatican will exclusively partner with NBS to host a stem cell summit in Rome in 2011 to highlight the practical use of these treatments and will also teach courses at all its universities and hospitals about the scientific advantages of adult stem cells, especially the VSEL, over other non-autologus stem cell treatments. This ringing endorsement of NBS's science will ensure continuous media attention as it has solved society's ethical dilemma of using non-autologus embyronic stem cells. The Vatican has backed the science and has stayed within its mandate of sustaining life. Compared to all other stem cell companies, NBS's treatments will begin to be marketed this year in China.

The company's first quarter revenues rose 24% over the same period last year to approximately $15.8 million. Continued growth would put them at over 80m in revenues for 2010.

Of major importance to investors should be the revelation in today's 8K filing that NBS has also signed an agreement with AQUA, a large investment fund, to enable NBS to draw down at its own discretion up to $20 million at a slight discount to market without warrants as an equity investment. This firm commitment from one of the premier investment institutions will provide NBS all the funding it needs, at the lowest dilution, to allow it to expand its fast growing Chinese pharma company and to market these proprietary stem cell treatments and benefit from times when their stock is performing extremely well. In other words, the company will raise money based on the good news that will be announced at the press conference, but there will not be a Rodman & Renshaw type financing deal that will dilute shares and chase away investors. According to BioMedReports, those shorts who thought NBS was doing a highly dilutive secondary financing have already initiated a bear attack using their usual ploys in order to start to cover. This key revelation should also alleviate those concerns for longs who were sitting on the sidelines waiting to jump in.

The company is scheduled to give updates on May 25th at a press conference at the NASDAQ market site and sources tell us that several major news outlets and newspapers have already begun to confirm their attendance at the event. In addition, the Catholic church may also be planning their own press events around this major news. This is the stock to own as traders and investors will run the price up in anticipation of those announcements to come in the days and weeks ahead.

The complete special report is available now at BioMedReports.Com:

Biotech investors interested in accessing the news portal's complete database of clinical trials and upcoming FDA decisions can access that information here:

About BioMedReports.Com is a news portal covering the biomedical news and financial sector. BioMedReports is not paid or compensated to report the news and developments of publicly traded companies.

For more biomedical sector and investment news go to

Contact Information

  • Media Contacts Only:
    Mary Davila
    Assistant Editor
    e-mail: Email Contact
    Tel: +1 323 472 4480
    Fax: +1 888 210 3556